Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FB102-101
- Development stage
- Unknown
- Lead developer
- argenx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FB102-101 (also known as FB102) is a proprietary monoclonal antibody developed by Forte Biosciences that targets CD122, the beta subunit of the interleukin-2 (IL-2) and interleukin-15 (IL-15) receptors. By binding to CD122, FB102 modulates the signaling of IL-2 and IL-15, which are critical regulators of natural killer (NK) cells and pathogenic T cell subsets. This mechanism is designed to treat autoimmune and inflammatory diseases by inhibiting the activity of these immune cells. The drug has been evaluated in a first-in-human Phase 1 SAD/MAD trial in healthy volunteers and a Phase 1b study in patients with celiac disease, where it demonstrated histological and symptomatic benefits. Forte Biosciences is being acquired by argenx due to the clinical potential of this asset.
- Other names
- anti-CD122 monoclonal antibodyanti-CD-122 monoclonal antibodyanti-CD 122 monoclonal antibody
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on FB102-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FB102-101.